Long‐term safety and tolerability of zavegepant 10‐mg nasal spray with concomitant use of anti‐calcitonin gene‐related peptide monoclonal antibodies or other select preventive migraine medications: Results from a phase 2/3 open‐label study
Self-administration of ZAV 10-mg nasal spray for the acute treatment of migraine up to 8 times/month for up to 52 weeks appeared well-tolerated irrespective of concomitant use of CGRP mAbs or OSPs.
Authors
- Robert J. Fountaine (ORCID: https://orcid.org/0000-0002-4105-1248)
- Samantha Sweeney
- Linda Mosher
- Kathleen Mullin (ORCID: https://orcid.org/0009-0005-7076-3497)
- Timothy W. Smith (ORCID: https://orcid.org/0000-0001-7219-9192)
- Gary Berman (ORCID: https://orcid.org/0000-0002-9297-9476)
Institutions
- Pfizer (United States) (US)
- Clinical Research Institute (US)
- New England Institute for Neurology and Headache (US)
- NeuroMetrix (United States) (US)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1111/head.14954
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47